Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat

Area of Science:

• Cardiovascular Research
• Metabolic Research
• Pharmacology

Background:

• Insulin resistance can cause lipid accumulation in non-adipose tissues, potentially damaging organs.
• Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists may help manage lipid imbalances.
• Angiotensin II infusion in rats can induce a hypertensive state with vascular lipid deposition.

Purpose of the Study:

• To investigate if pioglitazone, a PPARγ agonist, can decrease lipid accumulation in blood vessels induced by angiotensin II.
• To evaluate the effects of pioglitazone on oxidative stress and related molecular pathways in this hypertension model.

Main Methods:

• Rats received daily infusions of angiotensin II (0.7 mg/kg/day) for seven days to induce hypertension.
• Pioglitazone (2.5 mg/kg/day) was administered orally for seven days concurrently with angiotensin II.
• Lipid deposition and superoxide production were assessed using oil red O and dihydroethidium (DHE) staining, respectively.

Main Results:

• Pioglitazone significantly reduced angiotensin II-induced lipid deposition and superoxide production in the aortic adventitia.
• Increased superoxide signals, co-localized with lipid deposits, were primarily found in monocytes/macrophages.
• Pioglitazone inhibited the upregulation of LDL receptor and Nox1 expression and ameliorated the downregulation of PCSK9 expression caused by angiotensin II.

Conclusions:

• Pioglitazone effectively suppressed excess lipid accumulation and superoxide production in the aorta of rats with angiotensin II-induced hypertension.
• These findings suggest a potential therapeutic role for PPARγ agonists in managing vascular complications associated with hypertension and insulin resistance.